Business Context and Reporting Period
Company: Deckers Outdoor Corporation
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three and nine months ended September 30, 2000
Business Overview: The Company designs, markets, and distributes footwear under the Teva, Simple, and Ugg brands. Operations are segmented by brand and geography, with a significant portion of sales occurring in North America.
Key Financial Metrics
Nine Months Ended September 30, 2000
- Net Sales: $88,936,000 (Increase of 1.5% vs. prior year)
- Gross Profit: $40,237,000 (Gross Margin: 45.2%)
- Net Earnings: $6,221,000 (Earnings Per Share: $0.66 diluted)
- Operating Cash Flow: $19,839,000
- Cash and Cash Equivalents: $15,038,000 (as of Sept 30, 2000)
- Working Capital: $39,297,000
- Debt: No outstanding borrowings under the $50 million credit facility; $4,798,000 in outstanding letters of credit.
Three Months Ended September 30, 2000
- Net Sales: $19,023,000 (Increase of 4.3% vs. prior year)
- Net Loss: $(395,000) (Loss Per Share: $(0.04) diluted)
- Gross Margin: 37.8% (Improved from 31.4% in prior year)
Material Changes vs. Prior Period
- Profitability Improvement: Net earnings for the nine-month period increased 135.8% to $6.2 million, driven by improved gross margins (45.2% vs. 41.9%) and reduced selling, general, and administrative (SG&A) expenses as a percentage of sales (32.6% vs. 34.8%).
- Brand Performance:
- Teva: Sales were relatively flat for the nine months (-0.4%) due to weakness in the athletic retail channel, though Q3 sales increased 7.2% due to new hiker products.
- Ugg: Sales increased 31.6% for the nine months, driven by the "Street Collection" and strong fall early delivery.
- Simple: Sales increased 2.8% for the nine months, buoyed by U.S. market strength despite international weakness.
- Inventory Management: Inventories decreased 19.2% from year-end 1999, contributing to better cash flow and reduced closeout volume.
- Unusual Item: A nonrecurring charge of $375,000 was recorded in Q3 SG&A expenses to accrue for potential losses related to European anti-dumping duties dating back to 1997.
Guidance, Outlook, and Risks
Management Commentary and Outlook
- 2000 Sales Expectations: Teva sales expected to be relatively flat; Ugg sales expected to increase 10-15%; Simple sales expected to be flat to slightly up.
- Expense Outlook: SG&A as a percentage of sales is expected to be lower than 1999, though not as dramatic as the YTD improvement due to the non-recurrence of 1999 special charges.
- Liquidity: Management believes internally generated funds and the existing credit facility are sufficient for current and foreseeable working capital needs.
Risks and Contingencies
- Legal Proceedings: The Company is appealing a March 1999 jury verdict of $1,785,000 regarding trade secrets allegations. Management does not anticipate a material adverse effect.
- Anti-Dumping Duties: Potential exposure to European anti-dumping duties on footwear imported from China/Indonesia. A $375,000 reserve was recorded, but final determination remains uncertain.
- Seasonality: Results are highly seasonal; Teva sales peak in Q1/Q2, while Ugg sales peak in Q4. Weather conditions significantly impact demand.
- Teva Option: The Company holds an option to acquire Teva assets exercisable between 2000-2001 or 2006-2008. Exercise would require significant additional financing.
Investor Verification Checklist
- Verify the status of the European anti-dumping duty investigation and potential additional exposure beyond the $375,000 accrual.
- Monitor the outcome of the appeal regarding the $1.785 million trade secrets verdict.
- Assess the sustainability of the improved gross margins given the shift in product mix toward higher-priced Ugg footwear.
- Review the Company's ability to execute the Teva acquisition option if exercised, given the requirement for significant additional financing.
- Track the performance of the Ugg brand in the upcoming fourth quarter, which is historically the peak season for that product line.